- Research Article
- Open Access
5α-androstane-3α,17β-diol selectively activates the canonical PI3K/AKT pathway: a bioinformatics-based evidence for androgen-activated cytoplasmic signaling
© Springer Science+Business Media B.V. 2008
- Received: 29 November 2007
- Accepted: 14 February 2008
- Published: 27 February 2008
5α-Androstane-3α,17β-diol (3α-diol) is reduced from the potent androgen, 5α-dihydrotestosterone (5α-DHT), by reductive 3α-hydroxysteroid dehydrogenases (3α-HSDs) in the prostate. 3α-diol is recognized as a weak androgen with low affinity toward the androgen receptor (AR), but can be oxidized back to 5α-DHT. However, 3α-diol may have potent effects by activating cytoplasmic signaling pathways, stimulating AR-independent prostate cell growth, and, more importantly, providing a key signal for androgen-independent prostate cancer progression. A cancer-specific, cDNA-based membrane array was used to determine 3α-diol-activated pathways in regulating prostate cancer cell survival and/or proliferation. Several canonical pathways appeared to be affected by 3α-diol-regulated responses in LNCaP cells; among them are apoptosis signaling, PI3K/AKT signaling, and death receptor signaling pathways. Biological analysis confirmed that 3α-diol stimulates AKT activation; and the AKT pathway can be activated independent of the classical AR signaling. These observations sustained our previous observations that 3α-diol continues to support prostate cell survival and proliferation regardless the status of the AR. We provided the first systems biology approach to demonstrate that 3α-diol-activated cytoplasmic signaling pathways are important components of androgen-activated biological functions in human prostate cells. Based on the observations that levels of reductive 3α-HSD expression are significantly elevated in localized and advanced prostate cancer, 3α-diol may, therefore, play a critical role for the transition from androgen-dependent to androgen-independent prostate cancer in the presence of androgen deprivation.
- Androgen receptor
- Cell proliferation
- Gene expression
- PI3K/AKT pathway
- Prostate cancer
Androgens are responsible for physiological differentiation, growth, and maintenance as well as pathological development of androgen target tissues including the prostate. In mammals, the principal androgens are testosterone and its active metabolite 5α-dihydrotestosterone (5α-DHT) (McPhaul and Young 2001). Both testosterone and 5α-DHT bind and activate the androgen receptor (AR): 5α-DHT has a high affinity toward the AR with Kd (dissociation constant) = 10−10 M (Keenan et al. 1984), whereas the Kd of testosterone is approximately 1/3 of 5α-DHT (Grover and Odell 1975). After androgen binding, the ligand occupied AR translocates to the nucleus and leads to transcriptional activation of androgen responsive genes (ARGs) (Heinlein and Chang 2004).
In the prostate, 5α-DHT can be reduced to 5α-androstane-3α, 17β-diol (3α-diol) through the action of 3α-hydroxysteroid dehydrogenases (3α-HSDs). Two 3α-HSD isozymes, type 2 3α-HSD (AKR1C3) and type 3 3α-HSD (AKR1C2), are abundantly expressed in human prostate (Penning et al. 2000). Both 3α-HSDs possess dominant 5α-DHT reduction activity toward 3α-diol formation in vitro and in human prostate cells (Lin et al. 1997; Rizner et al. 2003). In contrast to 5α-DHT, the cellular responses to 3α-diol remain largely unknown. 3α-Diol has a low binding affinity to the AR (Kd = 10−6 M) (Penning 1997), is generally considered a weak androgen and, as of yet, has no defined hormonal action. Therefore, it is believed that 3α-diol must be first converted to 5α-DHT by oxidative 3α-HSDs before exerting an androgenic action (Jacobi et al. 1978; Bauman et al. 2006).
However, the above assumption could not explain 3α-diol’s action in a variety of androgen target tissues. 3α-Diol is more potent than 5α-DHT in the induction of prostatic hyperplasia in the castrated dog model (Walsh and Wilson 1976), and is involved in prostate formation in marsupial animals (Shaw et al. 2000). 3α-Diol has also been shown to be a critical hormone in virilizing the rat urogenital tract (Schultz and Wilson 1974), in the maintenance and regeneration of the prostate gland and seminal vesicles in a hypophysectomized rat model (Ahmad et al. 1978), and in parturition in a mouse model (Mahendroo et al. 1999). In addition, Wu et al. showed that elevated serum levels of 3α-diol metabolite in African-American and white men compared to Asian-American men, and suggested a correlation between 3α-diol metabolite and the increased prostate cancer risk seen in the first two groups (Wu et al. 2001). These reports suggest that 3α-diol may be an important hormone with its own functions through as yet undefined pathways.
However, the mechanism of 3α-diol-regulated cellular physiology remains largely unknown. Through gene expression profiling analysis, we identified that 3α-diol and 5α-DHT regulate distinct gene expression patterns in androgen sensitive human prostate cancer LNCaP cells (Nunlist et al. 2004; Zimmerman et al. 2004). In the present study, we identified potential 3α-diol-activated signaling pathways using bioinformatics approaches based on genes that are regulated by 3α-diol in human prostate LNCaP cells.
Reagents and chemicals
Human prostate cancer cell line LNCaP was obtained from ATCC (CRL-1740; Manassas, VA). 3α-Diol and mouse anti-β-actin antibody were purchased from Sigma-Aldrich (St. Louis, MO). [α-32P]dATP (3,000 Ci/mmol, 10 μCi/μl) was obtained from Amersham Pharmacia (Piscataway, NJ). RPMI 1640 medium, OPTI-MEM, penicillin–streptomycin, fetal bovine serum (FBS), and Lipofectamine 2000 were purchased from Invitrogen (Grand Island, NY). Charcoal-dextran treated (CD) FBS with testosterone levels <10−10 M was obtained from HyClone (Logan, UT). Atlas nylon Human Cancer 1.2 cDNA Expression Array was purchased from Clontech Laboratories (Palo Alto, CA). Rabbit anti-phospho AKT Ser(473) antibody was purchased from Cell Signaling Technology (Danvers, MA).
LNCaP cell culture, transfection, and 3α-diol treatment
LNCaP cells were maintained in the complete growth medium consisting of RPMI 1640 supplemented with 10% FBS, 5 units/ml penicillin, and 5 μg/ml streptomycin at 37°C and 5% CO2. Cells were passaged every 3–5 days or whenever cells reached 70–80% confluence. To perform androgen stimulation, 1 × 106 LNCaP cells were first seeded in 60 mm tissue culture plates, subjected to serum deprivation by culturing the cells with OPTI-MEM supplemented with 1% CD FBS for 24 h followed by 10–11 M (for array analysis) or 10−8 M (for Western blot analysis) 3α-diol stimulation.
To determine the involvement of the AR in 3α-diol-regulated cytoplasmic signaling, AR expression was suppressed by transfecting LNCaP cells with a plasmid-based siRNA construct as we previously described (Yang et al. 2005). Briefly, 2 × 106 LNCaP cells were first mixed with 3 μg AR specific (pSiAR-EGFP) or control siRNA (pSiCon-EGFP) plasmid in 100 μl of Nucleofector solution R, and transfection was accomplished using the Nucleofector transfection device (Amaxa Biosystems; Gaithersburg, MD). Cells were then returned to pre-warmed completed medium and incubated in a cell incubator for 24 h. Cells were then subjected to serum deprivation for another 24 h followed by 10−8 M 3α-diol stimulation.
cDNA-based membrane array hybridization and image acquisition
To identify transcription profiling in LNCaP cells following 3α-diol stimulation, cDNA-based membrane arrays were used. There were a total of 1,176 genes present in the Atlas Human Cancer 1.2 Expression Array. For a complete list of genes that were printed on these arrays, see http://www.clontech.com/products/detail.asp?product_id=10454&tabno=2. Procedures for total RNA isolation and quantitation, radiolabeled probes preparation and purification, as well as membrane hybridization and washing were described previously (Nunlist et al. 2004; Zimmerman et al. 2004). Following the washing steps, array membranes were exposed to phosphor-imaging screens (Packard BioScience; Meriden, CT); and images were captured by a Cyclone storage phosphorimager system (Packard BioScience). Results from the phosphor-imaging system were presented as digital light units and interpreted using OptiQuant image analysis software (Packard BioScience).
Data normalization and target gene identification
To perform array analysis, the background of the array membranes was first determined by the average and standard deviation (SD) of all 276 background spots, consisting of spots between probes areas and spots on the rims indicated in the array membranes for each array. Total system noise around the true zero point was normally distributed with right-tail positively skewed. Points exceeding 3 SD above the mean were eliminated until the true normal distribution was successively observed; usually this procedure involved the removal of no more than 5–10 points. The mean of the remaining background measurements was subtracted from all expression measurements as reported by others (Dozmorov and Centola 2003). Genes whose expression levels exceeded 2 SD above the background levels were considered to be expressed genes. In contrast, genes whose expression levels did not exceed the 2 SD thresholds were marked as below noise threshold (BNT). 3α-Diol-regulated genes were identified if their expression levels changed from BNT to exceed the 2 SD thresholds (off-on genes) or the opposite (on-off genes) following 3α-diol stimulation. Full microarray data were deposited in Gene Expression Omnibus (GEO) and are accessible on the GEO web-site (GSE8860).
Network generation and pathway analysis
The collective responsive genes were used to identify underlying pathways regulated by 3α-diol in prostate cells. The responsive genes were analyzed as one set by Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, Redwood City, CA, http://www.ingenuity.com), a web-based bioinformatics application, to identify canonical pathways over-represented in the data set. The identified pathways were then evaluated against the full expression data to identify each gene’s potential participation in 3α-diol-regulated cellular responses. The responsive genes were not ranked by gene expression levels.
Western blot analysis
Total cellular proteins were harvested following 3α-diol stimulation with RIPA buffer supplemented with proteinase inhibitors as we described (Yang et al. 2005). Protein concentration was determined by bicinchoninic acid (BCA) protein assay kit (Pierce; Rockford, IL). Total proteins separation and transfer were also performed as previously described procedures (Yang et al. 2005). Phospho-AKT and β-actin expression was detected by incubating protein membranes with appropriate primary antibodies against these molecules followed by peroxidase-conjugated secondary antibodies incubation. Immunoreactive proteins were detected using the enhanced chemiluminescent (ECL) reagent (Pierce).
Identification of 3α-diol responsive genes in human prostate cancer LNCaP cells
Genes overrepresented in Cell Cycle, PI3K/AKT, apoptosis and death receptor signaling canonical pathways. Expression level are shown as Log10 values
Before 3α-diol treatment
After 3α-diol treatment
Cell cycle controlling genes
Death receptor signaling
Identification 3α-diol-regulated signaling pathways using canonical pathway analysis
3α-Diol augmented PI3K/AKT signaling for prostate cell growth
Other branches of this pathway, such as cell cycle progression, cell death, cell survival, seemed to be unaffected, since genes involved these biological activities remained unchanged following 3α-diol treatment (Fig. 3). Analysis of the cell cycle genes showed that the majority of cell cycle regulators remained constant before and after 3α-diol administration indicating cell cycle progression remained constant even in the presence of 3α-diol. Up-regulation of some members of the apoptosis and death receptor signaling was observed; however, key blocks such as non-expression of BCL-2 and BAD apparently terminated transmission of cell death signals. Although the death receptor signaling pathway was up-regulated in response to 3α-diol, the activation of death receptor signaling apparently was countered by the activation of the PI3K/AKT survival pathway. In addition, 3α-diol-treated LNCaP cells might evade from cell death through an NF-κB-independent pathway, since IκB expression was up-regulated to prevent NF-κB from functioning in 3α-diol-treated cells.
3α-diol elevated AR-independent AKT activation
We and others have demonstrated that 3α-diol can be an active androgen with its own androgenic action (Nunlist et al. 2004; Agapova et al. 2006). More importantly, 3α-diol may play a significant role in promoting the development of androgen-independent prostate cancer through AR-independent mechanisms. This analysis was aimed at both identifying genes whose expression was altered and key pathways whose signaling was switched on or off following 3α-diol exposure in AR-positive human prostate cancer LNCaP cells. This report, therefore, would not only spotlight gene expression changes but also understand molecular processes that remain active or inactive in 3α-diol-stimulated prostate cells. We used 10−11 M 3α-diol to identify genes and pathways that are regulated by this androgen, since this concentration of 3α-diol stimulated elevated cell proliferation without significantly trans-activating AR in LNCaP cells (Nunlist et al. 2004).
To emphasize cancer progression, the cDNA membrane array used in this analysis focused on the central pathways represented in cancer, including cell cycle, growth factor signaling, cell death, and survival. Following the analysis of a total of 1,176 well-annotated, cancer-related genes, we have reported the confirmation of the unique expression patterns of 3α-diol versus 5α-DHT responsive genes using quantitative RT-PCR (Zimmerman et al. 2004), and Western blot analysis (Yang et al. 2008). We continued to investigate biological pathways that are affected by 3α-diol responsive genes, and to study roles of these pathways in regulating prostate cancer cell survival and growth.
Canonical pathway analysis suggested that apoptosis signaling and cytoplasmic signaling (PI3K/AKT and ERK/MAPK) were linked to 3α-diol-regulated prostate cell physiology or pathology. These cytoplasmic signaling pathways might be directly activated by 3α-diol without going through the AR, since (1) 5α-DHT was not detected in LNCaP cells following 3α-diol stimulation as determined by radiochemical assay (Rizner et al. 2003) and LC/MS/MS (Yang et al. 2008), (2) AR trans-activation activity was not significantly elevated with low concentrations of 3α-diol in LNCaP cells (Nunlist et al. 2004), and (3) AKT activation was observed in 3α-diol-stimulated, AR-silenced LNCaP cells. For the first time, the cytoplasmic signaling pathways, apoptosis signaling, and death receptor signaling were directly linked to 3α-diol-regulated biological effects in prostate cells. These findings underlie mechanisms of 3α-diol-stimulated prostate cancer cell growth and possibly androgen-independent prostate cancer progression.
We have demonstrated that LNCaP cells could not survive without functional AR (Yang et al. 2005); and supplementation of 5α-DHT did not protect AR-silenced LNCaP cells from undergoing apoptosis (Yang et al. 2008). In contrast, 3α-diol supported cell survival and proliferation in AR-silenced LNCaP cells and in AR negative human prostate cancer PC-3 cells (Yang et al. 2008). Based on these observations, we expected that genes associated with cell survival and/or apoptosis should appear as 3α-diol-regulated genes in the array analysis. Androgen removal did up-regulate pro-apoptotic genes; but inhibition of BCL-2 or BAD following 3α-diol administration might prolong prostate cell survival. In addition, the expression of cell cycle genes remained constant before and after 3α-diol stimulation suggesting that cells continue to undergo cell cycle progression in the presence of 3α-diol. Our bioinformatics analysis proposed potential signaling pathways that are responsible for 3α-diol-regulated androgenic effects such as suppression of apoptosis and promotion of cell growth to support prostate cancer cell survival and proliferation.
5α-DHT activates both genomic and non-genomic actions through AR trans-activation and cytoplasmic signaling, respectively. The interactions between the potent androgen and the AR have been studied in the most detail (Heinlein and Chang 2004). Although AR-dependent genomic action may ultimately turn out to be the most important for physiological development of androgen target tissues (Whitacre et al. 2002; Cheng et al. 2006), 5α-DHT-activated non-genomic action has been strongly implicated in pathological progression of androgen-independent prostate cancer (Sun et al. 2006; Cinar et al. 2007). In the mode of non-genomic action, it has been proposed that androgens may act as mediators of secondary transcription factors, as regulators of autocrine and paracrine mediators of gene expression, or as mediators in secretion of other hormones that regulate androgenic effects in androgen target tissues (Verhoeven and Swinnen 1999; Grillo et al. 2005). Some of these effects have been attributed to membrane AR (Papakonstanti et al. 2003; Grillo et al. 2005) or other plasma membrane bound receptors (Lieberherr and Grosse 1994; Estrada et al. 2003).
However, our findings suggested that at least some of AR-independent androgenic effects ascribed to 5α-DHT may result from the accumulation of 3α-diol in prostate cells. In the prostate, 5α-DHT can be reduced to 3α-diol through the action of reductive 3α-HSDs. Between the two major 3α-HSD isozymes, AKR1C2 and AKR1C3, in human prostate (Lin et al. 1997; Penning et al. 2000), both isozymes catalyze 5α-DHT reduction activity toward the formation of 3α-diol (Lin et al. 1997; Rizner et al. 2003). Elevated steady state levels of these 3α-HSD transcripts have been demonstrated in primary cultures of human prostate cancer cells as compared to epithelial cells derived from normal prostate (Lin et al. 1997; Rizner et al. 2003). Furthermore, elevated AKR1C3 expression has been demonstrated in localized and advanced prostate cancer (Nakamura et al. 2005; Fung et al. 2006; Stanbrough et al. 2006). Androgen deprivation therapy is intended to suppress the accumulation of potent androgens in the cancerous prostate. In contrast, levels of the potent androgens such as testosterone and 5α-DHT remain relatively constant in the prostate before and after androgen deprivation therapy (Nishiyama et al. 2004; Titus et al. 2005). With the elevated reductive 3α-HSD expression and availability of their substrate, it is possible that 3α-diol is accumulated in cancerous prostate even in patients undergoing androgen deprivation therapy. Based on the bioinformatics analysis presented in this study, potential 3α-diol accumulation may ultimately responsible for the development of androgen-independent prostate cancer.
3α-Diol can be an active androgen with its own androgenic function. To support the concept that 3α-diol can be responsible for prostate cancer progression in the presence of androgen deprivation therapy, we presented a bioinformatics evidence that 3α-diol can directly alter the status of PI3K/AKT as well as other apoptosis and cell growth pathways to promote prostate cell survival and proliferation in a cell culture system. The relationship between 3α-diol accumulation and androgen-independent prostate cancer progression deserves further investigation.
Androgen responsive gene
Below noise threshold
Fetal bovine serum
Gene expression omnibus
This work was supported by NIH R01 DK069808 to REH and by the US Department of Veterans Affairs Merit Award to HKL.
- Agapova OA, Malone PE, Hernandez MR (2006) A neuroactive steroid 5α-androstane-3α,17β-diol regulates androgen receptor level in astrocytes. J Neurochem 98:355–363PubMedView ArticleGoogle Scholar
- Ahmad N, Warren DW, Haltmeyer GC (1978) The effects of 5α-reduced androgens on maintenance and regeneration of prostate glands and seminal vesicles in castrated and hypophysectomized rats. Anat Rec 192:543–554PubMedView ArticleGoogle Scholar
- Bauman DR, Steckelbroeck S, Williams MV, Peehl DM, Penning TM (2006) Identification of the major oxidative 3α-hydroxysteroid dehydrogenase in human prostate that converts 5α-androstane-3α,17β-diol to 5α-dihydrotestosterone: a potential therapeutic target for androgen dependent disease. Mol Endocrinol 20:444–458PubMedView ArticleGoogle Scholar
- Cheng H, Snoek R, Ghaidi F, Cox ME, Rennie PS (2006) Short hairpin RNA knockdown of the androgen receptor attenuates ligand-independent activation and delays tumor progression. Cancer Res 66:10613–10620PubMedView ArticleGoogle Scholar
- Cinar B, Mukhopadhyay NK, Meng G, Freeman MR (2007) Phosphoinositide 3-kinase-independent non-genomic signals transit from the androgen receptor to Akt1 in membrane raft microdomains. J Biol Chem 282:29584–29593PubMedView ArticleGoogle Scholar
- Dozmorov I, Centola M (2003) An associative analysis of gene expression array data. Bioinformatics 19:204–211PubMedView ArticleGoogle Scholar
- Estrada M, Espinosa A, Muller M, Jaimovich E (2003) Testosterone stimulates intracellular calcium release and mitogen-activated protein kinases via a G protein-coupled receptor in skeletal muscle cells. Endocrinol 144:3586–3597View ArticleGoogle Scholar
- Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM, Lin HK (2006) Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13:169–180PubMedView ArticleGoogle Scholar
- Grillo ML, Jacobus AP, Scalco R, Amaral F, Rodrigues DO, Loss ES, Wassermann GF (2005) Testosterone rapidly stimulates insulin release from isolated pancreatic islets through a non-genomic dependent mechanism. Horm Metab Res 37:662–665PubMedView ArticleGoogle Scholar
- Grover PK, Odell WD (1975) Correlation of in vivo and in vitro activities of some naturally occurring androgens using a radioreceptor assay for 5α-dihydrotestosterone with rat prostate cytosol receptor protein. J Steroid Biochem 6:1373–1379PubMedView ArticleGoogle Scholar
- Heinlein CA, Chang C (2004) Androgen receptor in prostate cancer. Endocr Rev 25:276–308PubMedView ArticleGoogle Scholar
- Jacobi GH, Moore RJ, Wilson JD (1978) Studies on the mechanism of 3α-androstanediol-induced growth of the dog prostate. Endocrinology 102:1748–1755PubMedView ArticleGoogle Scholar
- Keenan BS, Greger NG, Hedge AM, McNeel RL (1984) Cytosol androgen receptor (AR) in human skin fibroblasts: characterization of the binding reaction and differentiation from androgen binding molecules of lower affinity. Steroids 43:159–178PubMedView ArticleGoogle Scholar
- Lieberherr M, Grosse B (1994) Androgens increase intracellular calcium concentration and inositol 1,4,5-trisphosphate and diacylglycerol formation via a pertussis toxin-sensitive G-protein. J Biol Chem 269:7217–7223PubMedGoogle Scholar
- Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA, Penning TM (1997) Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3α/17β-HSD activity and cellular distribution. Mol Endocrinol 11:1971–1984PubMedGoogle Scholar
- Mahendroo MS, Porter A, Russell DW, Word RA (1999) The parturition defect in steroid 5α-reductase type 1 knockout mice is due to impaired cervical ripening. Mol Endocrinol 13:981–992PubMedGoogle Scholar
- McPhaul MJ, Young M (2001) Complexities of androgen action. J Am Acad Dermatol 45:S87–S94PubMedView ArticleGoogle Scholar
- Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y, Sasano H (2005) In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 12:101–107PubMedView ArticleGoogle Scholar
- Nishiyama T, Hashimoto Y, Takahashi K (2004) The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10:7121–7126PubMedView ArticleGoogle Scholar
- Nunlist EH, Dozmorov I, Tang Y, Cowan R, Centola M, Lin HK (2004) Partitioning of 5α-dihydrotestosterone and 5α-androstane-3α, 17β-diol activated pathways for stimulating human prostate cancer LNCaP cell proliferation. J Steroid Biochem Mol Biol 91:157–170PubMedView ArticleGoogle Scholar
- Papakonstanti EA, Kampa M, Castanas E, Stournaras C (2003) A rapid, nongenomic, signaling pathway regulates the actin reorganization induced by activation of membrane testosterone receptors. Mol Endocrinol 17:870–881PubMedView ArticleGoogle Scholar
- Penning TM (1997) Moledular endocrinology of hydroxysteroid dehydrogenases. Endocr Rev 18:281–305PubMedGoogle Scholar
- Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N, Ratnam K (2000) Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 351:67–77PubMedPubMed CentralGoogle Scholar
- Rizner TL, Lin HK, Peehl DM, Steckelbroeck S, Bauman DR, Penning TM (2003) Human type 3 3α-hydroxysteroid dehydrogenase (aldo-keto reductase 1C2) and androgen metabolism in prostate cells. Endocrinology 144:2922–2932PubMedView ArticleGoogle Scholar
- Schultz FM, Wilson JD (1974) Virilization of the Wolffian duct in the rat fetus by various androgens. Endocrinology 94:979–986PubMedView ArticleGoogle Scholar
- Shaw G, Renfree MB, Leihy MW, Shackleton CH, Roitman E, Wilson JD (2000) Prostate formation in a marsupial is mediated by the testicular androgen 5α-androstane-3α,17α-diol. Proc Natl Acad Sci USA 97:12256–12259PubMedPubMed CentralView ArticleGoogle Scholar
- Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815–2825PubMedView ArticleGoogle Scholar
- Sun YH, Gao X, Tang YJ, Xu CL, Wang LH (2006) Androgens induce increases in intracellular calcium via a G protein-coupled receptor in LNCaP prostate cancer cells. J Androl 27:671–678PubMedView ArticleGoogle Scholar
- Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11:4653–4657PubMedView ArticleGoogle Scholar
- Verhoeven G, Swinnen JV (1999) Indirect mechanisms and cascades of androgen action. Mol Cell Endocrinol 151:205–212PubMedView ArticleGoogle Scholar
- Walsh PC, Wilson JD (1976) The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 57:1093–1097PubMedPubMed CentralView ArticleGoogle Scholar
- Whitacre DC, Chauhan S, Davis T, Gordon D, Cress AE, Miesfeld RL (2002) Androgen induction of in vitro prostate cell differentiation. Cell Growth Differ 13:1–11PubMedGoogle Scholar
- Wu AH, Whittemore AS, Kolonel LN, Stanczyk FZ, John EM, Gallagher RP, West DW (2001) Lifestyle determinants of 5α-reductase metabolites in older African-American, white, and Asian-American men. Cancer Epidemiol Biomarkers Prev 10:533–538PubMedGoogle Scholar
- Yang Q, Fung KM, Day WV, Kropp BP, Lin HK (2005) Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival. Cancer Cell Int 5:8PubMedPubMed CentralView ArticleGoogle Scholar
- Yang Q, Titus M, Fung KM, Lin HK (2008) 5α-Androstane-3α,17β-diol supports human prostate cancer cell survival and proliferation through androgen receptor-independent signaling pathways: implication of androgen-independent prostate cancer progression. J Cell Biochem (in press)Google Scholar
- Zimmerman RA, Dozmorov I, Nunlist EH, Tang Y, Li X, Cowan R, Centola M, Frank MB, Culkin DJ, Lin HK (2004) 5α-Androstane-3α,17β-diol activates pathway that resembles the epidermal growth factor responsive pathways in stimulating human prostate cancer LNCaP cell proliferation. Prostate Cancer Prostatic Dis 7:364–374PubMedView ArticleGoogle Scholar